Welcome to our dedicated page for Theralase Technologies news (Ticker: TLTFF), a resource for investors and traders seeking the latest updates and insights on Theralase Technologies stock.
Theralase Technologies Inc. reports company developments as a clinical-stage pharmaceutical developer of energy-activated small molecules for the destruction of cancer, bacteria and viruses. Its updates center on Ruvidar® (TLD-1433), including clinical and regulatory disclosures tied to non-muscle invasive bladder cancer and research into antiviral mechanisms such as HSV-1 inactivation.
Recurring announcements also cover operating and financial results, non-brokered private placements, line-of-credit financing, capital-structure disclosure, governance matters and development collaborations. The company’s news commonly links research progress with funding needs, regulatory pathways, intellectual-property considerations and commercialization risks for its small-molecule drug formulations.
Theralase (TSXV: TLT, OTCQB: TLTFF) received TSX Venture Exchange approval to list up to 20,399,050 common share purchase warrants under symbol TLT.WT, expected to start trading June 9, 2026.
The warrants and 19,166,667 units were issued in a brokered private placement raising C$4.6 million.
Theralase (OTCQB:TLTFF) reported Q1 2026 revenue of $132,634, up 45% year-over-year, with gross margin improving to 49% of revenue. Net loss narrowed to $1,031,785 as research and development spending declined while its Phase II NMIBC bladder cancer Study II nears completion.
Interim data show a 65.2% complete response rate (58/89) and 40.4% 12‑month durability (21/52), with the safety endpoint met in 82/82 patients. Theralase plans rolling NDA submissions to Health Canada and FDA in 3Q 2026, targeting decisions in 1H 2027.
Theralase (OTCQB: TLTFF) released audited 2025 financials and interim Study II clinical results for Ruvidar (TLD-1433) in BCG-unresponsive NMIBC CIS. Revenue fell 21% to C$816,468; net loss was C$4,120,817 in 2025. Interim efficacy: 65.2% complete response (58/89); 40.4% maintained CR at 450 days (21/52).
The company announced a collaborative clinical development agreement with Ferring and intends to file an NDS/NDA in 3Q2026 with decisions expected in 1H2027.
Theralase (OTCQB: TLTFF) reported a complete response in a preclinical orthotopic muscle-invasive bladder cancer (MIBC) animal study: 100% of animals treated with X‑Ray‑activated Rutherrin remained cancer‑free at study end, while radiation‑only and untreated groups showed progressive mortality.
The Kaplan–Meier analysis demonstrates durable survival benefit. Pending GLP toxicology, the company plans a Phase 0/I/II adaptive clinical study in MIBC in 2026, subject to regulatory approval.
Theralase (OTCQB: TLTFF) closed a combined financing totaling CAN$2.66 million on April 10, 2026, including a CAN$1.665M non-brokered unit offering and a CAN$1.0M revolving line of credit.
Units issued: 6,404,700 at CAN$0.26 (one share + one warrant, 5-year CAN$0.36 exercise). Insider subscriptions totaled 937,400 units. Proceeds will fund a Phase II NMIBC CIS study, GLP toxicology for Rutherrin, and working capital.
Theralase (OTCQB: TLTFF) reports a new mechanism explaining how Ruvidar inactivates herpes simplex virus 1 (HSV-1). Researchers measured zeta potential changes showing Ruvidar binds and neutralizes the virus surface charge, blocking cell entry.
In vitro, Ruvidar at ~1.3 µM produced up to an 8 log reduction (99.999999%) in infectious virions. Preclinical and clinical development for a topical HSV-1 treatment is slated to commence in 2026.
Theralase (OTCQB: TLTFF, TSXV: TLT) closed a non-brokered private placement of 4,230,770 Units at CAD 0.26 per Unit for gross proceeds of CAD 1.1 million on March 10, 2026. Each Unit includes one common share and one warrant exercisable at CAD 0.36 for five years.
Proceeds will fund the ongoing Phase II NMIBC clinical study, working capital and general corporate purposes. Securities are subject to a four-month-and-one-day hold expiring July 11, 2026, and final TSXV acceptance.
Theralase (OTCQB: TLTFF) reported preclinical data (March 9, 2026) showing X-Ray-activated Rutherrin significantly increased destruction of muscle invasive bladder cancer (MIBC) versus radiation alone. In mice, tumour sites had ~4x Rutherrin uptake; Rutherrin + radiation produced complete tumour clearance at day 35 versus persistent disease or humane endpoints with radiation alone.
The company plans a Phase 0/I/II adaptive clinical study of radiation-activated Rutherrin for MIBC, subject to regulatory approval.
Theralase (OTCQB: TLTFF) reported in vitro data showing that combining light-activated Ruvidar with recombinant human interferon alpha-2b produced substantially greater bladder cancer cell kill than interferon alone. Key finding: the combination yielded 50–65% higher total cell kill versus no Ruvidar across tested doses.
The results showed dose-dependent cytotoxicity for both agents and support a planned combinational clinical study for BCG-unresponsive NMIBC CIS patients.
Theralase (OTCQB: TLTFF) announced interim Phase II bladder cancer data will be presented at the 2026 European Association of Urology Congress (EAU26) in London, March 13-16, 2026. Enrollment in the BCG-unresponsive NMIBC CIS Study II is complete.
Results show early signals: 2 of 3 patients achieved complete response, 2 of 5 maintained response ≥15 months, and 1 of 5 showed ≥3 years duration after a single treatment. The company plans rolling regulatory submissions to Health Canada and the FDA beginning 3Q2026, with approval targeted in 2027.